Cargando…

TACkling Cancer by Targeting Selective Protein Degradation

Targeted protein degradation has emerged as an alternative therapy against cancer, offering several advantages over traditional inhibitors. The new degrader drugs provide different therapeutic strategies: they could cross the phospholipid bilayer membrane by the addition of specific moieties to extr...

Descripción completa

Detalles Bibliográficos
Autores principales: Noblejas-López, María del Mar, Tébar-García, David, López-Rosa, Raquel, Alcaraz-Sanabria, Ana, Cristóbal-Cueto, Pablo, Pinedo-Serrano, Alejandro, Rivas-García, Lorenzo, Galán-Moya, Eva M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610449/
https://www.ncbi.nlm.nih.gov/pubmed/37896202
http://dx.doi.org/10.3390/pharmaceutics15102442
_version_ 1785128257877704704
author Noblejas-López, María del Mar
Tébar-García, David
López-Rosa, Raquel
Alcaraz-Sanabria, Ana
Cristóbal-Cueto, Pablo
Pinedo-Serrano, Alejandro
Rivas-García, Lorenzo
Galán-Moya, Eva M.
author_facet Noblejas-López, María del Mar
Tébar-García, David
López-Rosa, Raquel
Alcaraz-Sanabria, Ana
Cristóbal-Cueto, Pablo
Pinedo-Serrano, Alejandro
Rivas-García, Lorenzo
Galán-Moya, Eva M.
author_sort Noblejas-López, María del Mar
collection PubMed
description Targeted protein degradation has emerged as an alternative therapy against cancer, offering several advantages over traditional inhibitors. The new degrader drugs provide different therapeutic strategies: they could cross the phospholipid bilayer membrane by the addition of specific moieties to extracellular proteins. On the other hand, they could efficiently improve the degradation process by the generation of a ternary complex structure of an E3 ligase. Herein, we review the current trends in the use of TAC-based technologies (TACnologies), such as PROteolysis TArgeting Chimeras (PROTAC), PHOtochemically TArgeting Chimeras (PHOTAC), CLIck-formed Proteolysis TArgeting Chimeras (CLIPTAC), AUtophagy TArgeting Chimeras (AUTAC), AuTophagosome TEthering Compounds (ATTEC), LYsosome-TArgeting Chimeras (LYTAC), and DeUBiquitinase TArgeting Chimeras (DUBTAC), in experimental development and their progress towards clinical applications.
format Online
Article
Text
id pubmed-10610449
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106104492023-10-28 TACkling Cancer by Targeting Selective Protein Degradation Noblejas-López, María del Mar Tébar-García, David López-Rosa, Raquel Alcaraz-Sanabria, Ana Cristóbal-Cueto, Pablo Pinedo-Serrano, Alejandro Rivas-García, Lorenzo Galán-Moya, Eva M. Pharmaceutics Review Targeted protein degradation has emerged as an alternative therapy against cancer, offering several advantages over traditional inhibitors. The new degrader drugs provide different therapeutic strategies: they could cross the phospholipid bilayer membrane by the addition of specific moieties to extracellular proteins. On the other hand, they could efficiently improve the degradation process by the generation of a ternary complex structure of an E3 ligase. Herein, we review the current trends in the use of TAC-based technologies (TACnologies), such as PROteolysis TArgeting Chimeras (PROTAC), PHOtochemically TArgeting Chimeras (PHOTAC), CLIck-formed Proteolysis TArgeting Chimeras (CLIPTAC), AUtophagy TArgeting Chimeras (AUTAC), AuTophagosome TEthering Compounds (ATTEC), LYsosome-TArgeting Chimeras (LYTAC), and DeUBiquitinase TArgeting Chimeras (DUBTAC), in experimental development and their progress towards clinical applications. MDPI 2023-10-10 /pmc/articles/PMC10610449/ /pubmed/37896202 http://dx.doi.org/10.3390/pharmaceutics15102442 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Noblejas-López, María del Mar
Tébar-García, David
López-Rosa, Raquel
Alcaraz-Sanabria, Ana
Cristóbal-Cueto, Pablo
Pinedo-Serrano, Alejandro
Rivas-García, Lorenzo
Galán-Moya, Eva M.
TACkling Cancer by Targeting Selective Protein Degradation
title TACkling Cancer by Targeting Selective Protein Degradation
title_full TACkling Cancer by Targeting Selective Protein Degradation
title_fullStr TACkling Cancer by Targeting Selective Protein Degradation
title_full_unstemmed TACkling Cancer by Targeting Selective Protein Degradation
title_short TACkling Cancer by Targeting Selective Protein Degradation
title_sort tackling cancer by targeting selective protein degradation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610449/
https://www.ncbi.nlm.nih.gov/pubmed/37896202
http://dx.doi.org/10.3390/pharmaceutics15102442
work_keys_str_mv AT noblejaslopezmariadelmar tacklingcancerbytargetingselectiveproteindegradation
AT tebargarciadavid tacklingcancerbytargetingselectiveproteindegradation
AT lopezrosaraquel tacklingcancerbytargetingselectiveproteindegradation
AT alcarazsanabriaana tacklingcancerbytargetingselectiveproteindegradation
AT cristobalcuetopablo tacklingcancerbytargetingselectiveproteindegradation
AT pinedoserranoalejandro tacklingcancerbytargetingselectiveproteindegradation
AT rivasgarcialorenzo tacklingcancerbytargetingselectiveproteindegradation
AT galanmoyaevam tacklingcancerbytargetingselectiveproteindegradation